Close Menu

Guardant Health, Bristol-Myers Squibb to Deploy Liquid Biopsies in Clinical Trials

NEW YORK (GenomeWeb) – Guardant Health said today that it is working with Bristol-Myers Squibb to develop the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.

Redwood City, California-based Guardant has struck similar partnerships with AstraZeneca, Merck, Merck KGaA, and Pfizer.

GuardantOMNI is designed to help investigators screen patients for multiple clinical trial options using a simple blood draw to enable real-time monitoring of tumor response and tumor evolution, and to support analysis of tumor mutational burden for use with immunotherapy trials, Guardant said.

"Our agreement with Guardant Health will allow us to further explore genomic biomarkers as we advance our clinical-stage pipeline," Bruce Car, head of translational sciences at Bristol-Myers Squibb, said in a statement. "Non-invasive methods of acquiring tumor DNA will provide more data, potentially leading to greater insights into patient response."

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.

Aug
18
Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
26
Sponsored by
Bionano Genomics

Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics. 

Sep
01
Sponsored by
Roche

This webinar will address the utility of exome sequencing for neurodevelopmental disorders research and will provide details of a comparison study of two exome probe kits in this field of study.